GSK, Zantac
Thousands of cancer patients in line to share £1.7bn as GSK settles Zantac cases
Tens of thousands of Americans are in line to share $2.2bn (£1.7bn) after GSK agreed a settlement over claims its indigestion drug caused cancers. The British drug giant has agreed to pay up to $2.2bn to settle tens of thousands of US lawsuits claiming its heartburn drug Zantac caused cancer.
Zantac maker GSK agrees to pay $2.3 bn in US settlements
Under the agreement, whose terms are confidential, GSK will make an "aggregate payment of up to $2.2 billion" to resolve these cases, the statement added.
Zantac Maker GSK Says It Reaches $2.3 Bn Settlement In US
British pharmaceutical company GSK said Wednesday it has agreed to pay $2.3 billion in the United States to put an end to lawsuits alleging that its Zantac heartburn drug caused cancer.
GSK Shares Soar on $2.2B Zantac Lawsuit Settlement
Shares of the UK-based pharma giant GlaxoSmithKline PLC ($GB:GSK) soared over 6% after the company announced a settlement of up to $2.2 billion
GSK jumps 6% after $2.2B Zantac settlement: why analysts see more upside
GlaxoSmithKline (GSK) saw its shares jump more than 6% after the pharmaceutical giant announced a settlement of up to $2.2 billion (€2.01bn) to resolve tens of thousands of lawsuits in the US related to its discontinued heartburn medication,
GSK shares jump on $2.2 billion Zantac settlement
By Maggie Fick and Yamini Kalia (Reuters) -GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S. lawsuits that alleged its discontinued heartburn drug Zantac caused cancer.
European stocks end lower after US inflation data; French budget in focus
European shares closed lower on Thursday, with defence and industrial stocks leading losses, after data showed U.S. inflation ...
Sanofi in Talks to Sell Controlling Stake in Consumer Health Arm to CD&R
Sanofi said it entered into talks with Clayton Dubilier & Rice to offload a controlling stake in its consumer-health division ...
pharmaphorum3d
GSK says new inhaler will help slash its carbon footprint
The first phase 3 trials are due to start in the first half of next year, using devices manufactured at GSK’s facility in Evreux, France. “If successful, this could lead to regulatory ...
Wall Street Journal3d
GSK to Pay Over $2 Billion in Bid to End Most U.S. Zantac Lawsuits
GSK GSK3.22%increase; green up pointing triangle agreed to pay more than $2 billion to settle almost all remaining liability cases in the U.S. over allegations its discontinued heartburn medicine ...
FiercePharma28d
ESMO: GSK's Zejula misses survival goal in first-line ovarian cancer, as pharma&'s combo disappoints
GSK’s Zejula boasts a broad U.S. approval as ... This month, the drug just won reimbursement in France for that first-line maintenance use, the company spokesperson said.
devdiscourse2d
European Markets in Flux as Inflation Data and Policy Moves Loom
European shares ended slightly lower, driven by losses in defence and industrial sectors, amid rising U.S. inflation and ...
Wall Street Journal on MSN2d
Health Care Roundup: Market Talk
Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET. 0544 ET – GSK’s $2.2 billion settlement to ...
Seeking Alpha28d
GSK, iTeos lung cancer therapy outperforms Jemperli in mid-stage trial
iTeos Therapeutics (NASDAQ:ITOS) announced Saturday that its experimental cancer doublet therapy developed with GSK (NYSE:GSK) outperformed the British drugmaker’s FDA-approved anti-PD-1 therapy ...
Too Old to Operate11d
Doxycycline PEP Reduces Bacterial STIs in MSM
The following is a summary of “Doxycycline prophylaxis and meningococcal group B vaccine to prevent bacterial sexually ...